ZYMEWORKS INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
ZYMEWORKS INC. (ZYME) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$11.37 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-06
- ZYMEWORKS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$3.62M.
- ZYMEWORKS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$7.75M.
- ZYMEWORKS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $1.33M, a 81.80% decline year-over-year.
- ZYMEWORKS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $3.34M, a 48.88% decline year-over-year.
- ZYMEWORKS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$23.65M, a 265.13% decline from fiscal 2024.
- ZYMEWORKS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $14.32M.
- ZYMEWORKS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$44.79M, a 269.15% decline from fiscal 2022.
- ZYMEWORKS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $26.48M, a 60.70% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$11.37M 10-Q · filed 2026-08-06 | -$10.03M derived: sum of 3 quarters · filed 2026-08-06 | -$6.69M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$7.75M 10-Q · filed 2026-05-07 | -$6.42M derived: sum of 2 quarters · filed 2026-05-07 | -$3.07M derived: sum of 3 quarters · filed 2026-05-07 | -$10.18M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $4.68M derived: sum of 2 quarters · filed 2026-03-02 | -$2.43M derived: sum of 3 quarters · filed 2026-08-06 | -$23.65M 10-K · filed 2026-03-02 | ||||
| 2025-09-30 | $3.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.76M derived: sum of 2 quarters · filed 2026-08-06 | -$24.98M 10-Q · filed 2025-11-06 | -$17.65M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$7.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$28.32M 10-Q · filed 2026-08-06 | -$20.99M derived: sum of 3 quarters · filed 2026-08-06 | -$14.45M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$21.22M 10-Q · filed 2026-05-07 | -$13.88M derived: sum of 2 quarters · filed 2026-05-07 | -$7.35M derived: sum of 3 quarters · filed 2026-05-07 | -$9.18M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $7.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $13.87M derived: sum of 2 quarters · filed 2026-03-02 | $12.04M derived: sum of 3 quarters · filed 2026-03-02 | $14.32M 10-K · filed 2026-03-02 | $14.34M 10-K · filed 2025-03-05 | |||
| 2024-09-30 | $6.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.71M derived: sum of 2 quarters · filed 2025-11-06 | $6.99M 10-Q · filed 2025-11-06 | $7.00M 10-Q · filed 2024-10-31 | -$15.34M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-06-30 | -$1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $449.00K 10-Q · filed 2025-08-07 | $458.00K 10-Q · filed 2024-08-01 | -$21.87M derived: sum of 3 quarters · filed 2026-03-02 | -$26.77M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-03-31 | $2.28M 10-Q · filed 2025-05-08 | $2.28M 10-Q · filed 2024-05-02 | -$20.04M derived: sum of 2 quarters · filed 2026-03-02 | -$24.94M derived: sum of 3 quarters · filed 2026-03-02 | -$14.24M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2023-12-31 | -$22.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$27.21M derived: sum of 2 quarters · filed 2026-03-02 | -$16.52M derived: sum of 3 quarters · filed 2026-03-02 | -$44.79M 10-K · filed 2026-03-02 | -$44.77M 10-K · filed 2024-03-06 | |||
| 2023-09-30 | -$4.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $5.80M derived: sum of 2 quarters · filed 2024-10-31 | -$22.47M 10-Q · filed 2024-10-31 | $15.10M derived: sum of 4 quarters · filed 2025-03-05 | ||||
| 2023-06-30 | $10.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$17.57M 10-Q · filed 2024-08-01 | $19.99M derived: sum of 3 quarters · filed 2025-03-05 | -$4.65M derived: sum of 4 quarters · filed 2025-03-05 | ||||
| 2023-03-31 | -$28.27M 10-Q · filed 2024-05-02 | $9.30M derived: sum of 2 quarters · filed 2025-03-05 | -$15.34M derived: sum of 3 quarters · filed 2025-03-05 | -$13.61M derived: sum of 4 quarters · filed 2025-03-05 | ||||
| 2022-12-31 | $37.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $12.93M derived: sum of 2 quarters · filed 2025-03-05 | $14.66M derived: sum of 3 quarters · filed 2025-03-05 | $26.48M 10-K · filed 2025-03-05 | ||||
| 2022-09-30 | -$24.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$22.91M derived: sum of 2 quarters · filed 2023-11-07 | -$11.09M 10-Q · filed 2023-11-07 | -$5.32M derived: sum of 4 quarters · filed 2024-03-06 | ||||
| 2022-06-30 | $1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $13.55M 10-Q · filed 2023-08-10 | $19.31M derived: sum of 3 quarters · filed 2024-03-06 | |||||
| 2022-03-31 | $11.82M 10-Q · filed 2023-05-08 | $17.58M derived: sum of 2 quarters · filed 2024-03-06 | ||||||
| 2021-12-31 | $5.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $16.48M 10-K · filed 2024-03-06 | ||||||
| 2021-09-30 | $10.71M 10-Q · filed 2022-11-08 | |||||||
| 2020-12-31 | $7.62M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |